Sanofi India declares 8% growth in net sales for Q4-2024
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Standalone profit from operations for Q4-2024 were Rs. 108 crore
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Subscribe To Our Newsletter & Stay Updated